Rinvoq ER 45 MG tablet UU 28S
Ended Awarded
- Contract number
- SPE2DB25FSGDR
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $140,506
Award facts
- Contract value 100% obligated
- $140,505.87 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $140,505.87 to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of RINVOQ ER 45 MG tablets (28-count units). This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The contract was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying a broad portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The DLA Medical Supply Chain leverages AmerisourceBergen's established infrastructure and supplier relationships to support Defense Health Agency operations and other federal healthcare systems globally. RINVOQ ER (upadacitinib extended-release), a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, represents the type of specialized pharmaceutical product that supports comprehensive military health service delivery requirements.
Quick answers
Who was awarded contract SPE2DB25FSGDR?
SPE2DB25FSGDR was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 29, 2025.
How much is contract SPE2DB25FSGDR worth?
The government has obligated $140,506 on SPE2DB25FSGDR.
Is contract SPE2DB25FSGDR an order under another contract?
Yes. SPE2DB25FSGDR is a delivery order under SPE2DB22D2211, an indefinite delivery contract.
Was contract SPE2DB25FSGDR competed?
The extent of competition for SPE2DB25FSGDR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award